Small Cell Lung Cancer | A New Era Is Beginning?

ISBN 10: 3036523014 / ISBN 13: 9783036523019

Published by MDPI AG, 2021

About this Item

Small Cell Lung Cancer | A New Era Is Beginning? | Buch | Gebunden | Englisch | 2021 | MDPI AG | EAN 9783036523019 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand.

Seller Inventory # 120825836

Bibliographic Details

• Title: Small Cell Lung Cancer | A New Era Is Beginning?
• Publisher: MDPI AG
• Publication Date: 2021
• Language: English
• ISBN 10: 3036523014
• ISBN 13: 9783036523019
• Binding: Buch
• Condition: Neu
• Dimensions: 250W x 175H x 14D millimeters 250 millimeters width by 175 millimeters height by 14 millimeters depth
• Weight: 575 grams
• Seller catalogs:
  • Bücher

About this title

Synopsis

Small-cell lung cancer (SCLC) is the most aggressive form of lung cancer: No significant progress has been made in finding new treatments for decades and platinum-based chemotherapy has for a long time represented the standard of care. This therapeutic scenario has recently changed, thanks to positive results in terms of improvement of overall survival obtained with a combination of checkpoint inhibitors (atezolizumab or durvalumab) with platinum-etoposide in patients with extensive disease. Moreover, nivolumab and pembrolizumab showed antitumor activity and received U.S. FDA approval as single agents in patients pretreated with platinum-based therapy and at least one other therapy. The improvement in the knowledge of the biology of SCLC has led to the development of new experimental therapies that have shown promising results, including poly (ADP-ribose) polymerase (PARP) inhibitors, anti-Notch ligand Delta-like protein 3 (anti-DLL3), antibody-drug conjugates, and aurora kinase inhibitors. Future challenges are the identification of predictive biomarkers for immunotherapy, the definition of the role of new biological agents, and the improvement of integrated approached for limited disease. This Special Issue will highlight the current state of treatment of extensive SCLC, focusing on the biology of SCLC, immune-checkpoint inhibitors, PARP inhibitors, and novel cytotoxic chemotherapy and radiotherapy techniques.